Jul 27, 2023 | Press Releases
SARASOTA, Fla., July 27, 2023 — INVO Bioscience, Inc. (Nasdaq: INVO) (“INVO” or the “Company”), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and...
Jun 27, 2023 | Press Releases
INVOcell now cleared for 5-day incubation period Supporting data reflects improved patient outcomes, similar to IVF SARASOTA, Fla., June 27, 2023 — INVO Bioscience, Inc. (Nasdaq: INVO) (“INVO” or the “Company”), a commercial-stage...
May 15, 2023 | Press Releases
Company to Host Conference Call Today at 4:30pm ET SARASOTA, Fla., May 15, 2023 — INVO Bioscience, Inc. (Nasdaq: INVO) (“INVO” or the “Company”), a commercial-stage fertility company focused on expanding access to advanced treatment...
May 8, 2023 | Press Releases
Financial results to be released after market close; Conference call to be conducted at 4:30 pm ET SARASOTA, Fla., May 8, 2023 — INVO Bioscience, Inc. (NASDAQ: INVO), a commercial-stage fertility company focused on expanding access to advanced infertility...
Apr 17, 2023 | Press Releases
Company to Host Conference Call Today at 4:30pm ET SARASOTA, Fla., April 17, 2023 — INVO Bioscience, Inc. (Nasdaq: INVO) (“INVO” or the “Company”), a commercial-stage fertility company focused on expanding access to advanced treatment...
Apr 11, 2023 | Press Releases
Financial results to be released after market close; Conference call to be conducted at 4:30 pm ET SARASOTA, Fla., April 11, 2023 — INVO Bioscience, Inc. (NASDAQ: INVO), a commercial-stage fertility company focused on expanding access to advanced infertility...
